Sequence 1 from Patent US 20060122119

General Information


DRACP ID  DRACP01265

Peptide Name   Sequence 1 from Patent US 20060122119

Sequence  EXAGIGILX

Sequence Length  9

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  X(2)=A or P; X(9)=T or Y

Chiral  L



Physicochemical Information


Formula  C30H49N7O8

Absent amino acids  CDFHKMNPQRSTVWY

Common amino acids  GIX

Mass  99865

Pl  3.85

Basic residues  0

Acidic residues  1

Hydrophobic residues  4

Net charge  -1

Boman Index  1164

Hydrophobicity  114.44

Aliphatic Index  141.11

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2006/0122119 A1

Patent Title  Peptides for use in antitumor immunotherapy.

Other Iinformation  Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002

Other Published ID  CA2477762A1  EP1481009A2  WO2003074565A2  WO2003074565A3 




DRACP is developed by Dr.Zheng's team.